A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity

被引:31
作者
Shi, ZD
Lee, K
Liu, HP
Zhang, MC
Roberts, LR
Worthy, KM
Fivash, MJ
Fisher, RJ
Yang, DJ
Burke, TR [1 ]
机构
[1] NCI, CCR, Med Chem Lab, NIH, Frederick, MD 21702 USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA
[3] SAIC Frederick, Prot Chem Lab, Frederick, MD 21702 USA
关键词
D O I
10.1016/j.bbrc.2003.09.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The growth factor receptor-bound protein 2 (Grb2) is an SH2 domain-containing docking module that participates in the signaling of numerous oncogenic growth factor receptor protein-tyrosine kinases (PTKs). Presented herein is a 5-methylindolyl-containing macrocyclic tetrapeptide mimetic (5) that binds to Grb2 SH2 domain protein with K-d = 75 pM. This represents the highest affinity yet reported for a synthetic inhibitor against any SH2 domain. In whole cell assays this novel analogue is able to effectively block the association of Grb2 to cognate cytoplasmic erbB-2 at IC50 < 10nM without prodrug derivatization or the addition of carrier peptide motifs. Anti-mitogenic effects against erbB-2-dependent breast cancers are achieved at non-cytotoxic concentrations (IC50 = 0.6 muM). Macrocycle 5 may be representative of a new class of therapeutically relevant Grb2 SH2 domain-directed agents. Published by Elsevier Inc.
引用
收藏
页码:378 / 383
页数:6
相关论文
共 48 条
  • [1] Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions
    Atabey, N
    Gao, Y
    Yao, ZJ
    Breckenridge, D
    Soon, L
    Soriano, JV
    Burke, TR
    Bottaro, DP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (17) : 14308 - 14314
  • [2] Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase
    Bradshaw, JM
    Mitaxov, V
    Waksman, G
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) : 971 - 985
  • [3] Bradshaw JM, 2003, ADV PROTEIN CHEM, V61, P161
  • [4] N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding
    Burke, TR
    Yao, ZJ
    Gao, Y
    Wu, JX
    Zhu, XF
    Luo, JH
    Guo, RB
    Yang, DJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2001, 9 (06) : 1439 - 1445
  • [5] Monocarboxylic-based phosphotyrosyl mimetics in the design of Grb2 SH2 domain inhibitors
    Burke, TR
    Luo, J
    Yao, ZJ
    Gao, Y
    Zhao, H
    Milne, GWA
    Guo, RB
    Voigt, JH
    King, CR
    Yang, DJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1999, 9 (03) : 347 - 352
  • [6] DALY RJ, 1994, ONCOGENE, V9, P2723
  • [7] Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: Implications for human breast cancer
    Dankort, D
    Maslikowski, B
    Warner, N
    Kanno, N
    Kim, H
    Wang, ZX
    Moran, MF
    Oshima, RG
    Cardiff, RD
    Muller, WJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) : 1540 - 1551
  • [8] High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia
    Feller, SM
    Tuchscherer, G
    Voss, J
    [J]. LEUKEMIA & LYMPHOMA, 2003, 44 (03) : 411 - 427
  • [9] Pathways downstream of Shc and Grb2 are required for cell transformation by the Tpr-Met oncoprotein
    Fixman, ED
    Fournier, TM
    Kamikura, DM
    Naujokas, MA
    Park, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (22) : 13116 - 13122
  • [10] Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways
    Fretz, H
    Furet, P
    García-Echeverría, C
    Rahuel, J
    Schoepfer, J
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (18) : 1777 - 1796